e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Challenges in tuberculosis control
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Forecasting the risk of medicinal complications from the chemical therapy in patients with multi-resistant pulmonary tuberculosis
F. Tashpulatova (Tashkent, Uzbekistan)
Source:
Annual Congress 2011 - Challenges in tuberculosis control
Session:
Challenges in tuberculosis control
Session type:
Thematic Poster Session
Number:
4370
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Tashpulatova (Tashkent, Uzbekistan). Forecasting the risk of medicinal complications from the chemical therapy in patients with multi-resistant pulmonary tuberculosis. Eur Respir J 2011; 38: Suppl. 55, 4370
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Related content which might interest you:
Risk of tuberculosis in pediatric patients treated with biological agents
Source: Virtual Congress 2020 – Aspects of acute and chronic airway infections in children
Year: 2020
The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 2s
Year: 2006
Secondary pulmonary mycoses etiology agent species diversity in patients with tuberculosis and in patients with HIV infection
Source: Virtual Congress 2020 – Mechanism or pathways of chronic lung diseases
Year: 2020
Monitoring of drug resistance of TB mycobacteria in new pulmonary TB patients
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Risk factors for infections with potentially resistant pathogens in patients in a pneumological intensive-care-unit
Source: Eur Respir J 2002; 20: Suppl. 38, 476s
Year: 2002
Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs
Source: Eur Respir J 2007; 30: Suppl. 51, 657s
Year: 2007
Previous antibacterial therapy and drug-resistance among pathogens in ICU patients with nosocomial pneumonia
Source: Eur Respir J 2001; 18: Suppl. 33, 405s
Year: 2001
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Non-pharmacological factors for the emergence of drug resistance in patients of pulmonary tuberculosis: An Indian overview
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
Sudden deaths amongst inpatients with active pulmonary tuberculosis following commencement of antimicrobial therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 158s
Year: 2003
Cardiovascular disease risk in patients with nontuberculous mycobacteria disease treated with macrolide
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
Application of therapeutic pneumoperitoneum for multi-drug resistant cavitary TB in HIV – infected patients
Source: Eur Respir J 2004; 24: Suppl. 48, 650s
Year: 2004
Macrolide therapy for pneumonia: balancing benefits with cardiovascular risks
Source: International Congress 2014 – ERS/JAMA lunchtime session: 2014 highlights
Year: 2014
Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries?
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Perspectives on antibiotic treatment of NTM pulmonary disease
Source: Eur Respir Monogr 2017; 75: 245-252
Year: 2017
Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease
Source: Eur Respir J 2006; 28: Suppl. 50, 131s
Year: 2006
Two major problems in TB patients today: MDR and the abandoned therapy
Source: Annual Congress 2011 - Challenges in tuberculosis control
Year: 2011
Pharmacoepidemiology of antibiotics using for treatment severe pulmonary infections in a clinical city hospital
Source: Eur Respir J 2005; 26: Suppl. 49, 640s
Year: 2005
Predictors of treatment failure among pulmonary tuberculosis patients in Pakistan
Source: International Congress 2019 – Tuberculosis: from diagnosis to complications
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept